An Open-label, Randomized, Two-way Crossover, Single Dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers

Trial Profile

An Open-label, Randomized, Two-way Crossover, Single Dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Dolutegravir/rilpivirine (Primary) ; Dolutegravir; Rilpivirine
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 25 Oct 2016 Status changed from recruiting to completed.
    • 17 Oct 2016 Planned number of patients changed from 86 to 118.
    • 08 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top